抗癌药物药物化学第二版 1849条(本栏目收费,不能显示细节,电话15274084725)
2. Estrogens and their involvement in carcinogenesis ....82 82
3. Antiestrogens as antitumor drugs ....87 87
3.1. Nonsteroidal antiestrogens (selective estrogen receptor modulators) ... 87 87
3.2. Steroidal antiestrogens ..... 92 92
4. Aromatase inhibitors .....96 96
4.1. Aromatase mechanism of action .... 97 97
4.2. Steroidal aromatase inhibitors (type I inhibitors) ... 98 98
4.3. C-19 modified substrate analogs ..... 99 99
4.4. 4-Hydroxyandrostenedione derivatives ... 100 100
4.5. Steroids with additional unsaturations at the A and B rings ... 100 100
4.6. Structure–activity relationships in steroidal aromatase inhibitors .. 102 102
4.7. Nonsteroidal aromatase inhibitors (Type II) .... 102 102
Alkylphosphocholines, 449–451 451
Allogeneic vaccines, 577 577
All-trans retinoic acid (ATRA, tretinoin), 123, 125–126 126
Altretamine (hexamethylmelamine, Hexalen®), 228, 229f 229
3.4. Inhibitors of LIM kinase ..... 382 382
4. Miscellaneous anticancer drugs acting on novel sites of tubuline ...383 383
5. Antivascular effects of microtubule-targeted agents ...385 385
2.1.1. Proteasome Inhibitors in Cancer Therapy .... 496 496
2.1.2. NEDD8-Activating Enzyme Inhibitors ... 503 503
2.1.3. APC Inhibitors .... 505 505
2.2. Inhibitors of Matrix Metalloproteinases .... 508 508
2.3. Inhibitors of Aminopeptidases ..... 512 512
2.4. Inhibitors of Cathepsins ..... 512 512
3. Heparanase Inhibitors ......515 515
3.1. Polysaccharides with O- or N-Sulfate Groups .... 516 516
3.2. Compounds with C-Sulfonate Groups ... 516 516
3.3. Neutral Inhibitors .... 517 517